Germany-based Immatics NV is to make its cell therapy platform available to Bristol Myers Squibb Co in order to develop a further cohort of immunotherapies for cancer. The collaboration, announced on 2 June, is an expansion of an existing partnership aimed at developing off-the-shelf cell therapies for solid tumours.
